. Author manuscript; available in PMC: 2012 Jul 11.

Published in final edited form as: Clin Genitourin Cancer. 2009 Jan;7(1):28–33. doi: 10.3816/CGC.2009.n.005

Table 5.

Best Objective Response to Sunitinib/Interferon-α Combination Therapy

Response	Sunitinib/IFN-α (N = 25)
Patients with Measurable Disease at Baseline, n (%)	25 (100)
Best Objective Response by RECIST, n (%)
PR	3 (12)
SD	20 (80)
PD	1 (4)
NA	1 (4)
Response Rate (CR + PR), n (%)	3 (12) (95% CI, 2.5–31.2)

Abbreviations: CR = complete response; IFN = interferon; NA = not assessed; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease